Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena.

A precursor-dependent model of indirect pharmacodynamic response which can describe tolerance and rebound was characterized in terms of the effects of changes in the fundamental properties of the drug on its response profiles. The model extends previous models by considering inhibition or stimulation of production of the response variable dependent on the amount of precursor which may accumulate or deplete after administration of some drugs. Standardized pharmacokinetic and pharmacodynamic parameters were used for generating dose, plasma concentration, and response-time profiles using computer simulations. The peak response (Rmax) and the time of its occurrence (TRmax) were dependent on the dose, degree of maximum inhibition (Imax) or stimulation (Smax), and drug concentrations causing 50% inhibition (IC50) or stimulation (SC50). The maximum rebound (RBmax) and the time of its occurrence (TRBmax) after a single bolus dose were also dependent on these factors, but were of lesser magnitude and showed relatively later occurrence. Interestingly, values of area between the baseline and effect curve (ABEC) and area between the baseline and rebound curve (ABRC) were equal for each set of conditions for each model, but the latter is reduced when there is a second pathway for loss of precursor. Tolerance occurs because of diverse mechanisms, and the response patterns demonstrated may be helpful in describing tolerance and rebound phenomena for drugs which affect precursor pools.

[1]  Perry,et al.  Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration. , 1980, The Journal of clinical investigation.

[2]  David R. Sibley,et al.  Molecular mechanisms of receptor desensitization using the β-adrenergic receptor-coupled adenylate cyclase system as a model , 1985, Nature.

[3]  S. Gottlieb,et al.  Prevention and reversal of nitrate tolerance in patients with congestive heart failure. , 1987, The New England journal of medicine.

[4]  M. Houston,et al.  Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. , 1988, American heart journal.

[5]  A. Guyton,et al.  Blood pressure control--special role of the kidneys and body fluids. , 1991, Science.

[6]  W J Jusko,et al.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.

[7]  E. Ekblad,et al.  A model eliciting transient responses. , 1984, The American journal of physiology.

[8]  Johan Gabrielsson,et al.  Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration , 1996, Clinical pharmacology and therapeutics.

[9]  A Schumitzky,et al.  A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.

[10]  J. Mandema,et al.  Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. , 1995, The Journal of pharmacology and experimental therapeutics.

[11]  M. Hammarlund-Udenaes,et al.  Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. , 1995, The Journal of pharmacology and experimental therapeutics.

[12]  W J Jusko,et al.  Integrated functions for four basic models of indirect pharmacodynamic response. , 1998, Journal of pharmaceutical sciences.